Information Library

Diabetes/Endocrinology

To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.

See all

  • Sort by:
  • Most Recent
  • Title

  • Precision Planning

    June 24, 2010
    For a Global trial, our customer worked with multiple players, including affiliates and an external CRO. With data coming from isolated teams across numerous language

  • Data-Driven Market Success

    May 14, 2010
    Steering the largest post-marketing diabetes study ever conducted, Quintiles was able to stay flexible and successfully scale up to an eight-country study with more than 55,000 patients, even with the operational challenges of multiple affiliates and staggered database locks.

  • Journal for Clinical Studies

    May 12, 2010
    In the March 2010 Journal for Clinical Studies, Dr. Erica Caveney and Dr. Rick Turner analyze the EMA Guidance on diabetes drugs and cardiovascular risk.

  • EMA’s Guidance on New Antidiabetic Drug Development

    May 12, 2010
    Assessing the EMA’s Guidance on New Antidiabetic Drug Development In January 2010, the European Medicines Agency (EMA) issued a draft guideline on antidiabetic drug development

  • Bridging Cultures

    May 9, 2010
    Takeda's growth strategy for Europe was to move into the Spanish market. Read how a Spanish team was assembled within a tight timeframe, with the help of Quintiles’ global and local reach, high profile in the marketplace, depth of experience and expertise.

  • Clinical – smarter trials, accelerated outcomes

    April 2, 2010
    Quintiles will work with you to plan and execute the smartest clinical trials and post-marketing studies, informed by a holistic view of strategic, operational, regulatory and marketplace issues.

  • Commercial – identify, promote and prove treatment value

    April 1, 2010
    Quintiles has built an unmatched suite of commercial competencies that biopharma companies are leveraging for faster market access and sustained success.

  • Data-Driven Patient Recruitment

    March 23, 2010
    Under pressure to deliver more evidence faster, drug developers are constantly searching for more patients for clinical trials.

  • Journal for Clinical Studies

    February 19, 2010
    In the January 2010 Journal for Clinical Studies, Dr. Erica Caveney and Dr. Rick Turner analyze the FDA Guidance on diabetes drugs and cardiovascular risk.

  • New FDA Guidance on Antidiabetic Therapies

    December 11, 2009
    Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program.

Page 1 of 2 (17 results)

Subscribe to Email Based on Your Interests

Set preferences